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ADH resistance of LLC-PK1 cells caused by overexpression of cAMP-
phosphodiesterase type-IV. The studies of animal models of nephrogenic
diabetes insipidus (NDI) suggest that abnormally high activity of cAMP
phosphodiesterase (cAMP.PDE) may cause unresponsiveness to the
diuretic effect of AVP. We explored whether overexpression of one of
the cAMP-PDE type isozymes, PDE-IV, in [8-ArgJ-vasopressin (AVP)
sensitive renal epithelial LLC-PK1 cells can prevent the hormone-
elicited cAMP increase. LLC-PK1 cells were stably transfected with
ratPDE3. 1 eDNA (which encodes for rolipram-sensitive PDE-IV),
inserted in plasmid pCMV5 and then were compared with sham-
transfected LLC-PK1 cells and wild LLC-PK1 cells. In the stably
transfected clone (LLC-PK1-S#16), the rolipram-sensitive PDE-IV
activity was about five times higher than in controls, whereas activities
of other types of PDEs were not different. The presence of cognate
mRNA for PDE-IV was confirmed by Northern blot, Whereas in the
control cells (wild LLC-PK1 cells and sham-transfected LLC-PK1
cells), the incubation with iO M AVP increased cAMP more than
tenfold, the LLC-PK1-S#16 cells with overexpressed cAMP-PDE were
resistant to cAMP-increasing effects of AVP and forskolin. However, in
the same LLC-PK1-S#16 cells the cGMP increases in response to
nitroprusside were not diminished. The AVP-dependent cAMP accu-
mulation in LLC-PK1-S#16 cells with overexpressed PDE-IV was
restored by addition of roliprams which decreased cAMP-PDE activity
to the levels similar to those in wild LLC-PK1 cells and sham-
transfected LLC-PK1-#Al cells. In contrast, inhibitors of other PDE
isozymes (PDE-I or PDE-II1) had little or no effect. Our findings show
that excessive activity of cAMP-PDE, in this case of isozyme PDE-IV,
can cause resistance to AVP which is analogous to that observed in
collecting ducts of mice with hereditary nephrogenic diabetes insipidus.
Multiple isozymes of cyclic-3' ,5 '-nucleotide phosphodi-
esterases (PDE)' and their isoforms are increasingly recognized
'PDE denotes cyclic-3' ,5'-nucleotide phosphodiesterase in general.
cAMP-PDE denotes PDE activity using cAMP as substrate, and
cGMP-PDE denotes PDE activity using cOMP as substrate.
In this report, the PDE isozymes are classified as proposed by Dr.
J.A. Beavo U, 31: According to this nomenclature, PIiE-1 is the family(also called "type") of PDE isozymes dependent on ionized calcium
(Ca2) and calmodulin (CaM); PDE-II is a family of isozymes cAMP-
PDE activity which is stimulated by low (M range) concentrations of
cGMP; the PDE-IIl are isozymes with low Km for cAMP and are
sensitive to inhibition by cilostamide, "cardiotonic inhibitors" and
cOMP, but are not inhibited by rolipram or Ro-20-1724; PDE-IV are
isozymes with very high affinity and selectivity for cAMP, are insensi-
tive to compounds that inhibit PDE-III and are selectively inhibited by
rolipram and Ro-20-l724; PDE-V are those isozymes which specifically
hydrolyze cGMP and activity of which is independent of Ca2-CaM.
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as critically important factors in intracellular signal transduc-
tion via cAMP and cGMP [1—6]. Results of our previous studies
of microdissected inner medullary collecting ducts from adre-
nalectomized rats [7] suggest that increased activity of cAMP-
PDE, suppressible by in vivo administration of glucocorticoids,
accounts for the partial hyporesponsiveness to antidiuretic
effects of [8-Arg]-vasopressin (AVP), Similarly, results of our
studies of collecting ducts from mice with hereditary nephro-
genic diabetes insipidus (NDI), so-called "NDI mice" [8—11],
indicate that abnormally high activity of cAMP-PDE [11],
namely the isozyme PDE-IV [8, 10], in cells of collecting ducts
is the key pathogenic factor that causes resistance of NDI mice
to the antidiuretic effect of AVP [8, 9].
In general, functional consequences of a decreased activity of
one or all PDE isozymes upon signal transduction via cAMP or
cGMP has been frequently studied in intact cells and tissues
with use of various PDE inhibitors [2, 3, 6, 12]. These inhibitory
compounds are either nonselective and decrease activities of all
five major types (families) of PDE [3], such as 3-methyl-I-
isobutyl-xanthine (IBMX) or papaverine [3, 12] or, more re-
cently developed PDE isozyme-specific inhibitors may selec-
tively decrease activities of various types of PDE isozymes,
such as, PDE-I, PDE-III, PDE-IV and PDE-V [3, 12]. These
type-selective PDE inhibitors have become increasingly em-
ployed as valuable experimental tools [3, 6, 12].
In contrast, pharmacologic agents which would enhance
activities of specific PDE isozymes in intact cells or tissues, and
which would thus permit the study of the consequences of
increased PDE activities upon cellular responses to hormones
in situ are virtually unknown. However, according to some
recent reports the increase in activity of PDE isozymes can be
achieved by genetic manipulation, namely by transfection of
cultured cells grown in vitro either with cDNA [13—15] or with
genomic DNA [16] encoding for PDE isozymes.
The LLC-PK1 renal epithelial cell line, which originated from
porcine kidney [17], serves frequently as a classic model for in
vitro studies of intracellular signal transduction via cyclic-3',5'-
nucleotides in renal epithelia [18—22]. This includes first and
foremost the action of AVP-mediated by cAMP [18, 19, 21, 22]
as well as effects of other regulatory agents, actions of which
are mediated by cGMP: endothelium-derived relaxing factor
(EDRF) and atriopeptins [20—22]. A comprehensive study [22]
of PDE isozymes in LLC-PK1 cells suggests that the isozymes
PDE-IV and PDE-I are predominant in LLC-PK1 cells and that
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PDE-IV appears to be the key PDE isozyme involved in the
control of cAMP generated in response to AVP [22].
To determine the impact of increased cAMP-PDE activity; in
particular the activity of PDE-IV isozyme which is most abun-
dant cAMP-PDE in these cells and is of major interest with
respect of AVP action upon cAMP dynamics in renal epithelial
cells [8—10, 22], we stably transfected LLC-PK1 cells with
cDNA ratPDE3.l [23], which encodes one of the isozymes of
PDE-IV family [1, 3—5].
We report the establishment of clones of stably transfected
LLC-PK1 cells in which the rolipram-sensitive PDE-IV activity
is overexpressed and the ability of AVP to increase cAMP level
is almost completely abolished. Our results thus document that
the abnormally high activity of cAMP-PDE, namely PDE-IV, in
renal epithelial cells can account for hyporesponsiveness [7] or
unresponsiveness [8, 9, 11] of renal cells to AVP, due to
abnormally rapid catabolism of cAMP.
Methods
LLC-PK1 cells [17] were grown in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 100 U/ml penicillin, 100 gJml, streptomycin,
amphotericin B and 2 mst glutamine, at 37°C in humidified 5%
CO2 and 95% air. As an expression vector, we employed
expression plasmid pCMV5 [13, 14] which contains promoter
and enhances region of human cytomegalovirus (CMV) as well
as the termination and polyadenylation signals of the human
growth hormone, and carries E. coli ampicillin-resistance gene
[13, 14]. The cDNA encoding PDE-IV isozyme ratPDE3.l (size
1.9 Kb) was inserted into a polylinker at an EcoRl restriction
site into pCMV5 plasmid, either in the sense or, for control
sham-transfection, in opposite orientation (these constructs are
further denoted "pCMV5-ratPDE3.l" and "pCMV5-rat-
PDE3.l-reverse," respectively). Plasmids were grown up in
DH-5c E. coil, the bacteria were harvested, lysed, and the
plasmids were isolated and purified using CsC1 ultracentrifuga-
tion. Analysis of the EcoRl restriction digests of pCMV-
ratPDE3 and control pCMV-ratPDE3-reverse constructs with
use of agarose gel electrophoresis confirmed the presence of
DNA bands corresponding to size of the pCMV5 plasmid and
ratPDE3. 1 cDNA, respectively.
Transient transfection
LLC-PK1 cells were plated in density 5 x io cells/dish and
incubated for one day. DNA transfection was performed using
CaPO4-DNA precipitation procedure, a variant employing BES
buffer solution [24]. The cells were incubated overnight under
3% CO, and then the precipitate was washed out with phos-
phate-buffered saline (PBS). The cells were washed, collected,
homogenized and centrifuged at 100,000 x g for 40 minutes [22,
25]. The supernatant was prepared and assayed for PDE
activities as described elsewhere [22, 25]. Wild LLC-PK1 cells
were transfected with 10 jg DNA (pCMV5-ratPDE-sense), and
the control cells were mock-transfected, that is, wild LLC-PK1
cells subjected to the same CaPO4-precipitation procedure but
without added DNA construct.
Stable transfection
The initial steps of transfection, for example, the CaPO4-
DNA precipitation procedure in BES buffer [24], were similar
to those outlined for the transient transfection. However, the
LLC-PK1 cells were then cotransfected [13] with 10 g of
pCMV5-ratPDE3.l (or pCMV5-ratPDE3.1-reverse) construct
plus 1 g of a selection plasmid pSV2-Neo encoding for
neomycin-resistance [26].
The culture flasks (75 cm2) were seeded with LLC-PK1 cells
at a density of 5 X l0 cells/mi. The cells were then cotrans-
fected with 10 ig pCMV5-ratPDE3.l (or 10 jIM pCMV5-
ratPDE3.1-reverse for sham-transfection) plasmid and 1 jg
pSV2Neo plasmid, and then grown in selection media contain-
ing geneticin (G418). In the preliminary experiment, we deter-
mined that 1 mg/mI of G418 in the growth medium is the
concentration lethal for all LLC-PK1 cells which are not carry-
ing the aminoglycoside-resistant plasmid pSV2-Neo. The
cotransfected cells were grown first in DMEM-10% FCS con-
taining 1 mg/ml G418. Four weeks later, when cells surviving in
medium with G418 grew to near-confluence and formed several
colonies in a flask, cells were trypsinized and made into cell
suspensions. After counting cell densities, we diluted suspen-
sions to a final cell density 2 cells/ml, and 0.5 ml aliquots of
diluted suspension were placed into each cloning well of culture
plates and grown further. Wells with either no grown colonies
of cells, or with two or more colonies growing in the same well,
were discarded; only wells which contained single colony were
selected and grown further. Cells reached confluency within
eight weeks of growth and were then subcultured in Petri
dishes; the concentration of G418 was then reduced from 1.0
mg/ml to 0.5 mg/ml in order to shorten the cell growth period. In
the course of cellular cloning, the extracts from the cells were
periodically prepared and assayed for PDE activities [22],
namely PDE-IV and cGMP-PDE.
Briefly, during several passes after reaching confluency, cells
were harvested, homogenized in a buffer containing 0.1%
Triton-X-100 [22] and the extract of the homogenate, prepared
as described previously [22], was assayed for several PDE
activities: the basal cAMP-PDE (without Ca2 and CaM), the
rolipram-sensitive PDE-IV (basal cAMP-PDE sensitive to inhi-
bition by 3 jIM rolipram) and, for comparison, also cGMP-PDE
activities, that is PDE-V (assayed without Ca2 + CaM) or
PDE-I, the Ca2-CaM-dependent cGMP-PDE [22]. We selected
and maintained 28 clones transfected with pCMVS-ratPDE3 .1
construct and resistant to G418, of which three clones showed
clearly higher (several-fold) cAMP-PDE and PDE-IV activities
as compared to the sham-transfectants and wild LLC-PK1 cells
(Table I). Several other stably transfected clones had consis-
tently but not extensively (=2x) increased PDE-IV activity. In
sham-transfectants all 17 surviving clones had PDE isozyme
activities similar to those found in wild LLC-PK1 cells (Table
1).
Preparation of the cell extracts
Prior to PDE assays, the LLC-PK1 cell monolayers were
rinsed twice with ice-cold phosphate-buffered saline (PBS) and
the cells were scraped into "homogenizing buffer" of the
following composition (final concentrations): 20 m TES (N-
tris[hydroxymethyl]methyl-2-aminoethane-sulfonic acid), 5 mM
MgC12, 1 msi EDTA [ethylenediaminetetraacetic acid], 1 mM
EGTA [ethylene glycol tris (/3-aminoethyl ether)-N,N,N1,N'-
tetraacetic acid], 5 mM /3-mercaptoethanol, 0.1 JiM leupeptin,
0.1 jIM pepstatin and 0.1 jIM phenylmethyl sulfonate fluoride
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Table 1. Activities of PDE isozymes in LLC-PK1 cells stably transfected with pCMV5-ratPDE3. I, sham-transfected with pCMV5-ratPDE3. 1-
reverse; and in wild LLC-PK1 cells
Total
cAMP-PDE PDE-IV
PDE-I (Ca2/CaM-dependent) PDE-V
without
Ca2/CaMcAMP-PDE cGMP-PDE
Transfectants
Clone
LLC-PK1-S#3 515 446 60 272 108
LLC-PK1-S#l6 1056 935 32 211 127
LLC-PK1-S#27 417 352 43 194 123Mean SE 662 198 577 180 45 8 225 24 119 6
Sham-transfectants
Clone
LLC-PK1-A#1 192 142 71 277 140
LLC-PK1-A#2 234 159 41 229 108
Mean SE 213 21 150 8 56 15 253 24 124 16
Wild LLC-PK1 cells
Sample
#1 210 138 NT NT 306
#2 160 102 151
#3 103 69 120
#4 215 140 156
Mean SE 172 26 112 17 183 41
Wild LLC-PK1 cells were assayed simultaneously with transfectants (for further details see Methods). NT = not tested. "Total cAMP-PDE"
denotes cAMP-PDE measured with 0.5 sM cAMP as a substrate in the absence of Ca2 and/or calmodulin in the assay medium. PDE-IV is
determined as total cAMP-PDE sensitive to inhibition with 3 a.,i rolipram; cilostamide (3 sM), a specific inhibitor for PDE-III [3, 10, 12] caused
less than 10% decrease in total cAMP-PDE.
a pmoles cAMP (or cGMP)/min/mg protein (mean of quadruplicates)
(PMSF), 0.1% Triton-X-l00, pH = 7.5 [10, 22, 25]. For prepa-
ration of cytosolic and membrane fractions from LLC-PK1
cells, the homogenization buffer was similar except it contained
0.3 M sucrose but no Triton-X- 100, as outlined previously [22].
The harvested cells were homogenized in a Potter-type Teflon-
glass homogenizer using 10 strokes. The homogenate was
ultracentrifuged at io x g for 40 minutes, supernatant retained
and pellet was, after rehomogenization, centrifuged again at i05
x g for 40 minutes. Supernatants from the first and second
ultracentrifugations were pooled into the "extract" [22, 251,
which was assayed for PDE activity. Homogenization and all
subsequent steps were conducted at 0 to 4°C. Subcellular
fractionation of LLC-PK1 homogenate to cytosol and mem-
branes was conducted using the same procedure as outlined in
our previous communication [22].
Phosphodiesterase (PDE) assay
The activity of PDE was measured always by incubating the
extracts or homogenate fractions in a reaction mixture (final
volume 100 p1) of the following composition (final concentra-
tions): 10 mrs MgSO4, 2 mri EGTA, 0.1% bovine serum
albumin, 15 mrs Tris-HC1 adjusted to pH 7.5, and either 0.5 M
[3H]-cAMP, or 0.5 LM [3H]-cGMP as substrate. In experiments
examining the activity of Ca2-calmodulin (CaM)-dependent
PDEs, the reaction mixture also contained 2.01 mM CaCI,, to
obtain 10 LM Ca2 [22, 25, 27], and 10 g/ml of calmodulin
(CaM). The PDE activity in aliquot samples incubated without
Ca2 and CaM (but containing 2 mrs EGTA, vide supra) was
subtracted as basal activity [22]. In experiments examining the
effect of PDE inhibitors, the stock solutions of all inhibitors of
PDE were made in 100% dimethylsulfoxide (DMSO), and the
incubation media (including controls) contained, after final
dilution, 0.1% (DMSO). Hydrolysis of cyclic-3' ,5'-nucleotides
was less than 20% of the substrate and was linearly proportional
to incubation time and enzyme protein [10, 22, 25]. Protein
content was measured by the Bradford's method [28].
Measurement of cAMP and cGMP levels in cultured cells
After serum-free media were aspirated off, cell layers were
first washed (twice) with warm (37°C) Kreb's Ringer buffer
(KRB) of following composition (final concentrations): 140 mM
NaCI, 5mM KCI, 1.2 mi MgSO4, 2 m CaC12, 2mM NaH2PO4,
10 mM Na-acetate, 10 mM D-glucose buffered to pH = 7.4with
20 ma HEPES. As with PDE assays (see above) PDE inhibitors
(when added) were dissolved in dimethyl sulfoxide (DMSO),
and final concentrations of DMSO were always 0.1%. As a
basic design, the cells were first incubated in 0.5 ml KRB
without inhibitors (controls) or with PDE inhibitors for 30
minutes in a shaking water bath (1 cycle/sec) at 37°C to allow
complete penetration of inhibitors into the cells [22, 25]. At the
end of the 30 minute incubation, the incubation medium was
aspirated off and replaced with medium of similar composition,
including an appropriate PDE inhibitor but also containing
[8-Argi-vasopressin (AVP), forskolin or sodium nitroprusside
(SNP). The basal values were controls without stimulant.
Incubation then continued for the next 10 minutes. At the end of
this second incubation period, the medium was removed and
0.5 ml of 10% trichloroacetic acid (TCA) and [3H]-cAMP or
[3H]-cGMP tracers for monitoring recoveries were added [22,
251. The cell culture plate was then placed in a shaking ice bath
to quantitatively extract cellular cAMP or cGMP; supernatant
was transferred into test tubes and kept at a 4°C. The TCA was
extracted by water-saturated ether and (cAMP and/or cGMP)
cyclic-3',S'-nucleotides were determined in duplicate by radio-
immunoassay (RIA) on pre-acetylated samples [22, 29, 30].
As determined in the control experiments, none of the PDE
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inhibitors employed herein, interfered with RIA for cAMP or
cGMP [22, 25]. The average cellular protein per well [22, 251
was determined by Lowry's method [311, after solubilization in
sodium dodecyl sulphate [321, in four wells treated similarly
(except for precipitation with 10% TCA) as the experimental
wells [22, 25]. Each data point (N = 1) reported represents the
average value from triplicate or quadruplicate wells.
RNA extraction and Northern blot analysis
Total RNA was extracted using, in principle, an extraction
procedure with guanidinium thiocyanate and phenol [33]. The
cells were homogenized in a premixed extraction solution,
RNAzoITMB, subsequent extraction of RNA by chloroform,
precipitation by isopropanol and final RNA washing in ethanol
was conducted using the protocol outlined in RNAZO1TM kit
(Tel-Test, Inc., Friendswood, Texas, USA). The RNA (10 sg
per lane) was resolved on 1% agarose electrophoresis, blotted
[34] onto ZetaBind nylon membrane and baked for two hours at
80°C. Each agarose gel included lanes with RNA size standards
(0.24 to 9.5 Kb Ladder, Gibco, BRL). The blots were prehy-
bridized in a Church's buffer [34] consisting of: 1% bovine
serum albumin, 7% sodium dodecyl sulphate (SDS), 1 mM
EDTA and 500 mri NaH2PO4 (pH = 7) for one hour at 65°C.
For hybridization purified 32P-radiolabeled cDNA probe was
added, dispersed in sonicated salmon sperm DNA (10 ng/ml),
and mixed with Church's buffer (see above), applied to the blot
and incubated at 65°C for 24 hours. Hybridization was carried
out with 32P-labeled cDNAs encoding ratPDE3.l,' then with
13-actin-cDNA and subsequently with ratPDE4. l-cDNA, rat-
PDE1.2-cDNA and ratPDE2. 1-eDNA [23].
cDNAs inserted in pGEM3Z plasmid were grown in DH5cs E.
coli, purified using CsCl centrifugation, and cDNAs were cut
out by digestion with EcoRI. cDNAs were separated from rest
of plasmid DNA on agarose electrophoresis and recovered from
the gel. The following cDNAs encoding for PDE-IV isozymes
were prepared and used for hybridization: ratPDEl.2 (2.7 Kb);
ratPDE2.1 (2.3 Kb); ratPDE3.1 (1.9 Kb); and ratPDE4.1 (2.4
Kb). The cDNA probes were randomly labeled using T7 DNA
polymerase ("Prime-H" kit, Strategene) and radiolabeled
probes were purified by gel filtration on spun-columns (Boe-
hringer-Mannheim, Indianapolis, Indiana, USA). The blots
were first hybridized with 32P-ratPDE3. 1 probe, washed at low
and high stringency conditions, and exposed to X-ray film
X-OMAT at —70°C. Then the 32P-ratPDE3.1 probe was
stripped and membranes were rehybridized with 32P-labeled
p-actin eDNA probe, and subsequently with 32P-ratPDE4. 1,
32P-ratPDEl.2 and 32P-ratPDE2.l cDNA probes. RNAs from
wild LLC-PK1 cells, from transfectants and from sham-trans-
fectants were analyzed simultaneously on the same blot.
PDE-LV type is family of PDE-IV isozymes with similar properties
and consists of four subfamilies discovered, based on molecular cloning
[23]. Nomenclature of all PDEs is not yet unified, however, PDE-IV
subfamilies cloned from rat tissues are here referred to according to
original description by Dr. M. Conti et al [23] (in parentheses is
abbreviation according to classification proposed by Dr. J.A. Beavo [1,
31): (a) ra(PDEI.2 (PDE-IV); (b) ratPDE2.1 (PDE-IVAI); (c) rat-
PDE3.1 (PDE-IVDI); and (d) ratPDE4.1 (PDE-IVB). The second num-
ber denotes isoform which is probably result of alternative splicing.
PDE-IV (hPDE-1) cloned from human monocytes [151 shows consider-
able homologies with ratPDE-I VA2 [1, 23].
In order to minimize variability from experiment to experi-
ment, effects of hormones and/or inhibitors were always tested
using the paired design [22, 25, 29, 301. Also, control wild
LLC-PK1 cells, stable transfectants (LLC-PK1-S#l6) or con-
trol sham-transfectants (LLC-PK1-A# 1) were seeded and
grown in wells on the same plates. These different variants of
LLC-PK1 cells were incubated in parallel, without (controls) or
with test agents (hormones, inhibitors), and simultaneously
extracts were prepared, and also all subsequent analyses were
conducted in parallel [22, 25, 29, 301. The content of cAMP or
cGMP was expressed in pmoles per mg protein. Each data point(N = 1) represents the mean from quadruplicate wells (cyclic-
3',5'-nucleotides) or quadruplicate PDE assays; "N" denotes
number of experiments.
Results were evaluated statistically using Student's t-test for
paired or for group comparisons, as specified in the Results.
Materials
Rolipram, 4-(3-cyclopentyloxy-4-methylphenyl)-2-pyrolidone
(ZK 62711) was a gift of Berlex Laboratories, Cedars Knolls,
New Jersey, USA. Cilostamide, N-cyclohexyl-N-methyl-4(1 ,2-
dihydro-2-oxo-6-quinohyloxy)butyramide(OPC-3639) was a gift
of Otsuka Pharmaceutical Company, Osaka, Japan. Ro 20-1724
(4-(3-butoxy-4-methoxybenzyl)-2-inidazolidinone was pur-
chased from BIOMOL; forskolin was purchased from Sigma
Chemical Co., St. Louis, Missouri, USA. 8-methoxymethyl,3-
isobutyl-l-methyl-xanthine (8-MeoM-IBMX) was a gift of Dr.
Jack N. Wells, Vanderbilt University, Nashville, Tennessee,
USA. 8-MeoM-IBMX is a potent specific inhibitor of Ca2-
calmodulin (CaM)-dependent PDE-I, but not by binding cal-
modulin [35]. In our previous experiments using cytosol from
rat inner medullary collecting duct cells [25], effects of
8-MeoM-IBMX on PDE were: For Ca2-CaM-dependent
cGMP the I.D.50 = 3.3 /LM, whereas for cAMP-PDE (without
Ca2) I.D.50 = 86 thus the selectivity of 8-MeoM-IBMX for
PDE-I was analogous to that originally found for PDE isozymes
from pig coronary arteries [35]. The QAE-Sephadex A-25 resin
was from Pharmacia, LKB, Inc. (Piscataway, New Jersey,
USA). Bovine brain calmodulin (CaM) was purchased from
Sigma Chemical Co. The cAMP-RIA kits were from BlO MED
TECH (BT-300); [8-3H]cGMP, ammonium salt, 10 to 30 Ci!
mmol was from Amersham Co. (TRK-392). Kits for cGMP-RIA
(NEX-133), [2,8-3H]-cAMP, ammonium salt, NEN (NEX 275)
30 to 50 Ci/mmol and 32P-a-dNTPs were purchased from
Amersham Co. (Arlington Heights, Illinois, USA). Nylon mem-
branes for blotting were Zeta-Probe GT were from Bio-Rad
Co.; the Random Primer Kit was purchased
from Strategene (La Jolla, California, USA); spun U-SO Sepha-
dex columns "Quick SpinTM for purification of 32P-radiola-
beled cDNA probes were from Boehringer Mannheim Corp.
RNAZO1TMB kit for isolation of RNA was purchased from
Tel-Test, Inc. The /3-actin eDNA (chicken) was purchased from
ONCOR® Inc. (Gaithersburg, Maryland, USA). RNA size
standards were 0.24 to 9.5 Kb RNA ladder stainable by ethid-
ium bromide from GIBCO BRL (Life Technologies, Inc.,
Gaithersburg, Maryland, USA). Films for autoradiograms were
X-OMAT AR Kodak diagnostic film from Eastman Kodak Co.
(Rochester, New York, USA). All other reagents and chemi-
cals, all of the highest purity grade, were purchased from
standard suppliers. [3H]-cAMP and [3H]-cGMP were, prior to
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Fig. 1. Transient transfection, Activities of PDE isozymes in mock-
transfected and transiently-transfected LLC-PK1 cells. Each bar de-
notes mean SEM of N = 3 experiments. Symbols are: (0) control
mock-transfected cells; () transfected cells. PDE-V is defined as
cGMP-PDE activity assayed in the absence of Ca2/CaM. PDE-I
(Ca2ICaM-dependent PDE) was assayed either with cAMP (left side)
or with cGMP (right side) as substrates [22, 25]. * Value significantly
different from control (P < 0.001, t-test).
use as substrates or for recovery measurements in RIA for
cAMP and cGMP, purified according to method of Kincaid and
Manganiello [36].
Results
Transient transfection
Initially, in transiently transfected LLC-PK1 cells, we deter-
mined activities of major PDE isozyme types using the estab-
lished responsiveness to the specific synthetic inhibitors and/or
modulators [2, 22, 25]. In transiently transfected LLC-PK1
cells, the cAMP-PDE activity (controls: 85 7 pmol cAMP/
mm/mg protein, mean SE, N = 3) was increased (P < 0.02;
t-test) about tenfold (transfected: 1024 222 pmol cAMP/
mm/mg protein, mean SEM, N = 3), whereas no significant
difference in the activity of cGMP-PDE was found (Fig. 1).
As portrayed in Figure 1, all increases in cAMP-PDE activity
could be accounted for by the enhancement of PDE type-IV, as
determined by cAMP-PDE activity sensitive to inhibition by 3
/SM rolipram, the maximum inhibitory dose [22, 25]. On the
other hand, no significant differences were found in PDE-III as
determined by cAMP-PDE sensitive to inhibition by 3 tM
cilostamide (data not shown), or in PDE-V, the cGMP-PDE
activity independent of Ca2/CaM (Fig. 1). Likewise, there
were no differences in Ca2/CaM-dey,endent PDE-I when as-
sayed either with cGMP or with cAMP as substrates (Fig. 1).
These results indicate that the employed conditions for tran-
sient transfection were favorable for selective and very pro-
nounced expression of PDE-IV in LLC-PK3 cells (Fig. 1). To
determine whether transfection might have changed the subcel-
lular localization of PDE-IV, PDE was assayed in the cytosolic
and membrane (100,000 x g pellet) fractions prepared as
described in detail in our preceding communications [22, 251.
Both in control (wild LLC-PK1 cells) and in transiently-trans-
fected LLC-PK1 cells with overexpressed PDE-IV, the activi-
ties of PDE-IV were predominantly found (>80%) in the
cytosol (data not shown).
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Fig. 2. Time-course of the activities of PDE-IV (A) and cGMP-PDE
assayed without Ca2/CaM (PDE-V) (B) in two clones of stably
transfected LLC-PK1 cells. Symbols are: (—• U—) clone LLC-PK1-
S# 16 stably transfected with construct pCMV5-ratPDE3. 1; (--A--A -
-)
control, that is, sham-transfected cells, clone LLC-PK1-A#l. Each
point is an average of 3 to 4 replicate samples. The clones were
propagated in multiple passages and, at the time points indicated on
abscissae, the extract from aliquots of cells was prepared and assayed
for PDE activities. At all time points, the PDE-IV activity in transfec-
tants LLC-PK1-S#l6 was always at least fivefold higher than in
sham-transfectants LLC-PK1-A#l, whereas activities of cGMP-PDE
were not significantly different between the two cell lines.
Stable transfection
In experiments with stably transfected LLC-PK1 cells (de-
tailed in the Methods), LLC-PK1 cells also stably transfected,
but with a construct containing ratPDE3. 1 gene cDNA inserted
into pCMV5 vector in the opposite orientation (further referred
to as "sham transfectants"), served as major controls. In some
studies, we also compared properties of the transfectants with
properties of wild LLC-PK1 cells as an additional control.
The cellular clones of stably transfected LLC-PK1 cells,
selected by growing in G418, were repeatedly tested for the
activity of PDE-IV and, for comparison, with activity of cGMP-
PDE (Fig. 2). From initial pool of surviving cellular clones,
several sense-transfectant lines were found to have PDE-IV
activity at least several times higher than in sham transfectants
or in wild LLC-PK1 cells (Table 1).
In further experiments, we studied stably transfected LLC-
PK1 cells clone designated "LLC-PK1-S#16" as a transfectant
with highly expressed PDE-IV (Table 1, Figs. 2, 7). The
LLC-PK1-S#16 cells have PDE-IV activity about fivefold
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Table 2. The content of cAMP and cGMP in transfectants (LLC-PK1-S#16 cells), sham-transfectants (LLC-PK1-A#l cells) and in wild LLC-
PK1 cells
Transfectants, with
Sham-transfectant overexpressed PDE-
controls (LLC-PK1- IV (LLC-PK1-S#16 Controls (wild LLC-
A#l cells) P valuea cells) P valuea PK1 cells)
cAMP levels
Basal (no additions) 6.4 0.3 (18) <0.001 4.05 0.27 (18) NS 4.9 0.73 (7)
l0- M AVP 74.8 5.lc (18) <0.001 8.1 0.4c (18) <0.01 72.2 54C (7)
l0 M AVP + iO M Rolipram
lO M AVP + l0— M Cilostamide
332.8 260b (15)
80.8 13.6 (11)
<0.001
<0.001
76.5 77d,e (15)
7.79 0.4 (11)
—
—
M AVP + 5x105 M 8-MeoM-IBMX 225.8 (11) <0.001 12.55 10b,d (11)
i0 M Forskolin 169.0 24.7k' (11) <0.001 9.04 0.4(11) —
cGMP levels
Basal (no additions) 2.41 0.2 (18) NS 2.85 0.17 (18) MS 3.23 0.48 (4)
iO M SNP 50.27 43C (14) <0.001 93.14 9.8 (14) <0.001 46.4 6.75' (4)
Levels of cAMP or cGMP are expressed in pmoles cAMP (or cGMP)/mg protein after 10 minutes incubation. Each value denotes mean SEM
of (N) number of samples. The activities of PDE-IV and, for comparison cGMP-PDE, measured in extracts from aliquots of cells from these
experiments are shown in Fig. 4.
All cAMP or cGMP values of wild LLC-PK1 cells are not significantly different (I-test) from another controls
a Significance of difference between LLC-PK1-S#16 and controls (I-test)b cAMP significantly higher than with AVP alone (I-test)
Value with AVP alone significantly higher than basal cAMP value, or cGMP value with SNP significantly higher than basal cGMP (t-test)d Significantly different from AVP + rolipram (I-test)
Not significantly different from each other
higher than in wild LLC-PK1 cells (Table 1, Fig. 2). Cells of this
clone were compared with sham-transfected cells, a clone
designated "LLC-PK1-A#l ," which has normal PDE-IV and
other PDE isozyme activities the same as wild LLC-PK1 cells
(Table 1). Manyfold overexpression of PDE-IV and no differ-
ence in cGMP-PDE activities in LLC-PK1-S#l6 cells and
control LLC-PK1-A#l cells were consistent in multiple pas-
sages (Fig. 2). Based on preliminary experiments, transfectant
LLC-PK1-S#16 was chosen for comparison with sham-trans-
fectants "LLC-PK1-A# 1" since the difference in PDE-IV
activity between these two lines was similar to difference in
activity of this isozyme between collecting ducts of normal mice
and NDI-mice unresponsive to AVP (Fig. 7; see also footnote
#3).
The activity of cAMP-PDE in extracts from the LLC-PK1-
S#l6 cells with overexpressed PDE-IV showed similar sensi-
tivity to the inhibitory action of rolipram, a typical inhibitor of
PDE-IV [3—5], as did cAMP-PDE from control LLC-PK1-A#l
cells. In both cell lines, the maximum inhibition was achieved at
3 M rolipram and the half-maximum inhibitory doses (ID50) of
rolipram were virtually identical: for LLC-PK1-A#l ID50 =
0.17 /LM and for LLC-PK1-S#16 ID50 = 0.14 LM rolipram.
Relative proportion of residual cAMP-PDE activity, that is,
activity in the presence of 3 lM rolipram, was similar in
LLC-PK1-S# 16 cells (25%) and sham-transfected LLC-PK1 -
A#1 cells (24%).
In the presence of maximum inhibitory doses of rolipram (3
ELM), the residual cAMP-PDE activity was always higher in
transfectant LLC-PK1-S# 16 than in other cells. Since rolipram
inhibits PDE-IV competitively, the PDE-IV activity cannot be
suppressed completely, namely at the lower concentrations
when rolipram is highly selective for PDE-IV compared to other
isozymes [31. For example, at 3 M rolipram, the residual
cAMP-PDE activity in LLC-PK1-S#l6 cells (110 28 pmoll
mm/mg protein; N = 9) was significantly (P < 0.025; t-test)
higher than residual cAMP-PDE activity in sham-transfectants
LLC-PK1-A#l cells (35 4 pmollmin/mg protein; N = 9) and
in wild LLC-PK1 cells (38 5 pmol/min/mg protein; N = 7).
The "LLC-PK1-A#1" cells did not differ significantly from
wild LLC-PK1 cells either in PDE isozyme activities (Table 1)
and in cyclic-3' ,5'-nucleotide dynamics (Table 2, Fig. 7). Based
on all these results it can be predicted that after addition of the
maximum inhibitory dose of rolipram to transfectants LLC-
PK1-S#16 with overexpressed PDE-IV, the resulting cAMP-
PDE activity will be similar to or not appreciably different from
cAMP-PDE in wild LLC-PK1 cells and sham transfectants
without added rolipram (Table 2, Fig. 7).
RNA extracted from both transfectants (LLC-PK1-S#16) and
sham-transfectants (LLC-PK1-#Al), and from wild LLC-PK1
cells was subjected to Northern blot hybridization analysis [13,
14, 23, 37]. As shown in Figure 3, only RNA of transfectant
cells (LLC-PK1 -S# 16) with very high activity of PDE-IV (Table
1, Fig. 4) showed the presence of cognate mRNA encoding
ratPDE3. 1 isozyme, whereas RNAs from the sham-transfec-
tants (LLC-PK1-A#l) or from wild LLC-PK1 cells did not
hybridize with 32P-ratPDE3. 1 cDNA probe at all (Fig. 3). All
the three types of cells showed positive hybridization with
32P-cDNA probe for p-actin (Fig. 3). The nylon membrane was
subsequently rehybridized with 32P-labeled cDNA probes for
other PDE-IV isoforms cloned from rat tissue, that is, rat-
PDE4.l, ratPDEl.l and ratPDE2.l [4, 5, 23]. RNA from wild
LLC-PK1 cells or from sham-transfectant LLC-PK1-A#l cells
did not hybridize with any of the four tested probes for cDNA
coding for various PDE-IV isozymes under either high or low
stringency conditions. Moreover, RNA from LLC-PK1-S#16
cells hybridized only with 32P-cDNA-ratPDE3. 1 (Fig. 3) and not
with the other three homologous probes (data not shown).
Dynamics of cAMP and cGMP in transfectants
Transfectants, LLC-PK1-S#16 cells, with highly expressed
PDE-IV (Fig. 4), were compared with control, sham-trans-
fected LLC-PK1-A#1 cells for their ability to accumulate

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Fig. 3. Northern blot analysis of RNA from transfectants (LLC-PK1-S#16) as compared with two controls: wild LLC-PK1 cells and
sham-transfectant (LLC-PK,-A#1). Total RNA was prepared from harvested confluent cells as described in the Methods section, separated on 1%
agarose gel (10 RNA per lane), blotted and hybridized with 32P-labeled cDNA-ratPDE3. 1(A). The RNA from transfectant LLC-PK1-S#16 cells
hybridized with 32P-cDNA-ratPDE3. 1 at 2.3 Kb spot. Probe was then stripped and the membrane rehybridized with 32P-labeled $-actin cDNA, spot
at 1.9 Kb (B). Thereafter, the membrane was again rehybridized with 32P-labeled cDNA probes for ratPDEl .2, ratPDE2. 1, and ratPDE4. 1 [221.
None of the 32P-cDNA-ratPDE probes except ratPDE3. 1 hybridized with either transfectants, wild LLC-PK1 or the sham transfectants.
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Fig. 4. Activities of PDE-IV and PDE-V
(cGMP-PDE independent of Ca2 k/CaM) in
extracts fro,n aliquots of cells in which cAMP
and cGMP dynamics were determined. Each
bar denotes mean SEM from N = 3 to 5
experiments. * Value significantly different
from both controls (sham-transfectants or wild
LLC-PK1 cells). NS denotes values not
significantly different from each other (P>
0.05, i-test).
slightly (by —38%) albeit statistically significantly lower than
the control LLC-PK1-A#l cells and did not differ significantly
from basal cAMP levels in wild LLC-PK1 cells (Table 2).
In response to stimulation by AVP in control sham-trans-
fected LLC-PK1-#Al cells the cAMP levels increased many-
fold (% + 1117 146, mean SEM; N = 5, P < 0.001; paired
t-test) and even more in response to forskolin (Fig. 5). In
cAMP in response to iO M AVP, a hormone concentration
which in our previous study elicited maximum cAMP accumu-
lation in LLC-PK1 cells [221. The LLC-PK1-S#16 cells differed
dramatically from LLC-PK1-A#1 controls in the extent of
cAMP accumulation, namely in response to stimulation to AVP
and to forskolin (Fig. 5). As shown on Table 2 and Figure 5, the
basal cAMP levels in LLC-PK1-S#16 transfectants were only
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Fig. 5. Dynamics of cAMP and cGMP in
sham-transfectant controls (LLC-PK,-A#1
cells) and in transfectants (LLC-PK1-S#16
cells). (A) The levels of CAMP In LLC-PK1-
S#16 cells had significantly higher PDE-IV
activity than sham-transfectants, whereas
cGMP-PDE activities were not different. Each
bar denotes mean SEM of N = 3 to 5
experiments; values in each experiment are an
average from N = 3 to 4 replicate cell culture
wells. In control LLC-PK1-A#l cells and in
LLC-PK1-S#16 cells the cAMP values with
AVP and forskolin (FSK) were significantly
higher (t-test) compared to the basal value.
The relative (%) increases in cAMP
compared to basal value were also significant
(paired t-test). * Values in transfectants (LLC-
PK1-S#16 cells) significantly (1-test) lower
than corresponding value in sham-transfected
controls (LLC-PK1-A#l cells). Likewise, the
relative (A%) increases in response to AVP
and FSK in LLC-PK1-S#16 cells were
significantly (t.test) lower than in sham-
transfected controls (LLC-PK1-A#l). (B) The
cGMP levels in transfectants (LLC-PK1-S#16
cells) and sham-transfectant controls (LLC-
PK1-A#l cells). Each bar denotes mean
SEM from N = 3 to 5 experiments. * Values
significantly different (paired 1-test; P < 0.02)
from sham-transfected controls
(LLC-PK1-A# 1).
Fig. 6. Effect of specific inhibitors of PDE
isozymes upon cAMP accumulation in
transfectants with overexpressed PDE-IV
(LLC-PK1-S#16 cells) and in sham-
transfected controls (LLC.PK1.A#I cells).
Each bar denotes mean SEM from N = 3 to
5 experiments (see also legend to Fig. 5). (A)
Transfectants with overexpressed PDE-IV
(LLC-PK1-S# 16); (B) sham-transfectant
controls (LLC-PK1-A#l cells). * Values
statistically significantly higher (1-test) than
cAMP in the presence of AVP but without
inhibitors. The relative (z %) increase
compared to cAMP value with AVP alone is
indicated over the bars. Note the different
scale of ordinates for transfectants (A) and
controls (B). The extent of cAMP
accumulation in the presence of AVP alone in
sham-transfectant controls (LLC-PK1-A# 1
cells) was not significantly different from the
AVP-dependent cAMP accumulation in
transfectants (LLC-PK1-S#16 cells) incubated
in the presence of 10 M rolipram.
contrast, in the transfectant LLC-PK1-S#16 cells, the rise of
cAMP in response to AVP was reduced by more than 90% (Fig.
5); the stimulatory effect of forskolin upon cAMP accumulation
was also greatly (by 95%) reduced (Fig. 5, Table 2). Observa-
tion that AVP-dependent and, similarly, the forskolin-depen-
dent cAMP accumulations were both nearly abolished in trans-
fectant LLC-PK1-S# 16 cells (Fig. 5, Table 2) argues against the
possibility that the transfection maneuver caused lesions in the
membrane signal transduction, either loss of AVP receptors or
uncoupling of AVP receptors from adenylate cyclase. The
extent of cAMP accumulation in response to AVP in the
sham-transfected LLC-PK1-A#1 cells was not different from
AVP-induced accumulation in another cell type in which the
cAMP-PDE activity was not increased, that is, in wild LLC-
PK1 cells (Table 2, Fig. 7). Taken together, these observations
suggest that the enhanced activity of cAMP-PDE (Fig. 7), in
particular PDE-IV (Fig. 4; Results), determines to a larger
degree the cAMP accumulation when cells are stimulated by
AVP (or forskolin) than the basal, that is, unstimulated levels of
cAMP (Table 2, Figs. 5 and 7).
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Fig. 7. Restoration of the A VP-dependent cAMP accumulation and
inhibition of cAMP-PDE in transfectant LLC-PK1-S#16 cells with
overexpressed PDE-IV by rolipram. (A) AVP-dependent cAMP accu-
mulation. All cells were incubated for 10 minutes with l0— M AVP and
cAMP determined. (B) cAMP-PDE activities and effect of rolipram.
The activity of cAMP-PDE in extracts from the same cell types in which
cAMP levels were measured. Symbols are: (D) control cell clones, that
is, sham-transfected LLC-PK1-A#l cells and wild LLC-PK1 cells; ()
LLC-PK1-S#16 transfectants incubated without or with rolipram, or
cAMP-PDE activities in extracts from the cells assayed without or with
rolipram. Each bar denotes mean SEM from N = 7 to 9 samples or
assays. * Values significantly (t-test, P < 0.005) different from all other
values. Controls were not significantly different from each other or from
transfectant LLC-PK1-S#16 cells or extracts incubated in the presence
of rolipram.
The basal accumulation of cGMP in stably transfected LLC-
PK1-S# 16 cells, was not significantly different (Fig. 5, Table 2)
from basal cGMP in sham-transfected LLC-PK1-#Al controls
(Fig. 5) or from basal cGMP in wild LLC-PK1 cells (Table 2).
The cGMP levels increased in response to incubation with 1 mti
SNP to significantly higher degree ( + 53 8%, P < 0.02; N
= 3; paired t-test) in LLC-PK1-S# 16 transfectants than in
control sham-transfected LLC-PK1-A#l cells (Fig. 5) and in
wild LLC-PK1 cells (Table 2). However, the SNP-stimulated
cGMP levels were not different between sham-transfected
LLC-PK1-A#l cells and wild LLC-PK1 cells (Table 2). It
should be recalled that neither the cGMP-PDE activity inde-
pendent of Ca2/CaM (isozyme type PDE-V), nor Ca2/CaM-
dependent cGMP-PDE (isozyme type PDE-I) did differ between
LLC-PK1-S#16 and LLC-PK1-A#1 cells (Table 1, Fig. 4).
Experiments examining the effect of isozyme-specific PDE
inhibitors show that only rolipram, a specific inhibitor of
PDE-IV isozymes [3, 4], increased markedly (+809 165%,
mean SEM, N = 4, P < 0.02; paired t-test) the AVP-
dependent cAMP levels in LLC-PK1-S#16 cells (with overex-
pressed cAMP-PDE; Figs. 6 and 7; Table 2). The AVP-stimu-
lated accumulation of cAMP in transfectant LLC-PK1-S#16
cells incubated with rolipram reached the same levels as in
sham-transfected LLC-PK1-A#l cells or in AVP-stimulated
wild LLC-PK1 cells in response to AVP alone (Table 2, Fig. 7).
Cilostamide, the specific inhibitor of PDE-III [3—6], had no
detectable effect, and 8-MeoM-IBMX, the specific inhibitor of
PDE-I [25, 35], caused only very small ( + 50 5%, mean
sEM; N 3, P < 0.01, paired 1-test), but significant increase of
cAMP content in response to AVP in transfectant LLC-PK1-
S#l6 cells (Table 2, Fig. 6).
Effects of the same inhibitors upon AVP-dependent cAMP
accumulation were also examined in LLC-PK1-A#1 cells with
normal (not increased) activities of PDEs (Figs. 5 and 7).
Similar to LLC-PK1-S#16 cells, cilostamide showed no effect
whereas rolipram enhanced AVP-dependent cAMP levels.
However, the relative enhancing effect of rolipram (% in-
crease) in sham-transfected LLC-PK1-A#1 cells (% + 360
56, N = 4; P < 0.05, paired 1-test) was significantly (P < 0.05,
1-test) lesser than in transfectants LLC-PK1-S#16 (%+ 809
165, N = 4; P < 0.02) with overexpressed PDE-IV. The
inhibitor of PDE-I, 8-MeoM-IBMX [35], increased the AVP-
dependent cAMP accumulation in the sham-transfectant LLC-
PK1-A#1 cells to a somehow lesser degree (%+ 278 108, N
3) than did the rolipram (Fig. 7, Table 2). Thus, rolipram
showed much higher relative (A%) AVP-enhancing effect in
LLC-PK1-S#16 transfectants with overexpressed PDE-IV than
in controls. In contrast, the relative (%) AVP-enhancing action
of 8-MeoM-IBMX was more pronounced in control LLC-PK1-
A#1 cells than in transfectant LLC-PK1-S#16 cells with over-
expressed PDE-IV (Fig. 6).
The AVP-stimulated cAMP accumulation was determined in
sham-transfected LLC-PK1-A#l cells, wild LLC-PK1 cells and
compared with cAMP in transfectant LLC-PK1-S#16 cells with
overexpressed cAMP-PDE, mainly PDE-IV, incubated without
or with rolipram (Fig. 7). The concentration of rolipram was
aimed, based on testing of susceptibility of cAMP-PDE in
various cell lines, to rolipram (Results) to inhibit PDE-IV to
such a degree so that cAMP-PDE activity in transfectants
would be comparable to sham-transfectants and wild LLC-PK1
cells without the inhibitor (Fig. 7). Indeed, in extracts from
LLC-PK1-S#16 cells with added of maximum inhibitory dose of
rolipram the cAMP-PDE activity in the transfected LLC-PK1-
S#16 cells is reduced to cAMP-PDE activities of non-trans-
fected cells (Fig. 7B). To sum up, the cAMP content was greatly
reduced in LLC-PK1-S#16 transfectants with overexpressed
PDE-IV (Fig. 7). But when in the same LLC-PK1-S#16 cells
rolipram reduced cAMP-PDE activity towards those of LLC-
PK1 cells and wild LLC-PK1 cells (Fig. 7, Results), the AMP-
dependent cAMP accumulation was the same as the values
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found in wild LLC-PK1 cells and sham-transfected LLC-PK1-
A#1 cells (Fig. 7).
Discussion
The previous studies suggested that increased cAMP catab-
olism via cAMP-PDE may play an important role in the
diminished [7] or absent [8, 11] response of renal epithelial cells
to AVP. Therefore, we investigated the impact of experimen-
tally increased PDE activity upon AVP-dependent dynamics of
cAMP in the renal epithelial LLC-PK1 cell line. Unlike in
experimental evaluation of decreased PDE activity, which can
be accomplished with the use of various PDE-type-specific
inhibitors [3, 6, 121, specific stimulators of PDE isozymes in
intact cells are not currently available. However, stable trans-
fection of cells with eDNA [13, 38] or genomic DNA [16] coding
for PDE isozymes can result in selective enhancement of PDE
isozyme activities, and this strategy was used in the present
study.
The profile of major PDE isozymes found in LLC-PK1 cells,
a well-established model for study of AVP-regulated cAMP
dynamics, was recently determined [22] and apparently
PDE-IV plays a special or dominant role in AVP-dependent
cAMP metabolism of LLC-PK1 cells [22]. Further, PDE
isozyme type IV is of prime interest since excessively high
PDE-IV activity is the major cause of resistance of collecting
ducts to AVP in murine hereditary nephrogenic diabetes insip-
idus found in NDI mice [8—111. In view of these considerations,
we investigated the impact of increased PDE-IV activity due to
transfection of LLC-PK1 cells with the cDNA coding on of
PDE-IV variant, the "ratPDE3.1" [13, 14]. The cDNA coding
for PDE-IV isozyme ratPDE3. 1 was chosen for transfection out
of four major PDE-IV subtypes cloned from rat cells and tissues
[23], in view that the expression of PDE-IV activity encoded by
gene ratPDE3. I could be, prospectively, further modulated by
experimental maneuvers in vitro [13] and in vivo [14].
Transient transfection of LLC-PK1 cells, which resulted in
tenfold isozyme-specific increase of PDE-IV activity (Fig. 1)
showed that LLC-PK1 cells are well-suited both to accept the
ratPDE3. 1 cDNA inserted in pCMV5 plasmid and to express
PDE-IV activity [13, 14]. Cotransfection with pCMV5-rat-
PDE3.l construct and selection plasmid pSV2-neo and subse-
quent cell cloning produced several cell lines with selective and
prominent increase of rolipram-sensitive PDE-IV (Table 1),
which persists for numerous passages (Fig. 2). The clone
LLC-PK1-S#16 was chosen for further studies since these cells
have increased PDE-IV activity to a similar extent2 as collecting
duct cells of NDI mice [8]. LLC-PK1 cells sham-transfected
with pCMV5-ratPDE3. 1-reverse construct yielded cell lines
which showed no differences in appearance, growth rate, PDE
isozyme activities (Table 1) and cAMP/cGMP dynamics (Table
2, Fig. 7) as compared to wild LLC-PK1 cells. The sham-
transfected LLC-PK1-A#1 cells were employed as main con-
trols, since those cells underwent analogous prolonged experi-
2 Based on data reported in our previous study [8] and additional
experiments, we assessed the difference between activities of rolipram-
sensitive PDE-IV in niicrodissected inner medullary collecting ducts of
control and NDI mice. In collecting ducts of NDI mice, the activity of
PDE-IV was 4.6 times higher than in control mice (T.P. Dousa et al,
unpublished observations).
mental manipulation as the transfectants LLC-PK1-S# 16.
However, wild LLC-PK1 cells in terms of PDE activites and
cAMP/cGMP dynamics did not differ tangibly from the sham-
transfectants (Table 2, Fig. 7).
An appreciable number of cognate mRNA transcripts in
LLC-PK1-S#16 cells was readily detected by Northern blot
(Fig. 3). Although the quantity of PDE-IV isozyme protein was
not yet directly measured, the aforementioned findings strongly
indicate that the increased PDE-IV activity in LLC-PK1-S#16
cells was due to synthesis of additional PDE-IV isozyme due to
new mRNA coded by ratPDE3. 1 cDNA, rather than to activa-
tion of PDE-IV enzyme pre-existing in LLC-PK1 cells [22].
Lack of hybridization of 32P-cDNA-ratPDE3.l and three
other homologous cDNA probes with RNA from wild LLC-PK1
cells is surprising, since PDE-IV activity is abundant in these
cells and can be chromatographically resolved into several
fractions [22]. The cAMP-PDE from transfectants and sham-
transfectants shows similar sensitivity to rolipram (Results) and
polyclonal antibody raised against polypeptide sequence from
ratPDE3.1 isozyme [37] recognized PDE-IV in cellular fractions
from wild LLC-PK1 cells [22].
Although the basal levels of cAMP in the stable transfectants
were slightly lower than in controls (Fig. 5, Table 2), the major
differences were seen in cells with enhanced cAMP synthesis
by the potent stimuli, that is, AVP (Fig. 5, Table 2). In
transfected LLC-PK1-S#16 cells, more than tenfold stimula-
tory effects on cAMP levels of both AVP and forskolin were
virtually abolished (Fig. 5, Table 2). Studies with the use of
isozyme-speciñc PDE inhibitors (Fig. 6) indicated that stimula-
tory effect of AVP on cAMP levels was restored by the specific
PDE-IV inhibitor rolipram (Figs. 6 and 7; Table 2).
In experiments comparing cAMP-PDE activities and sensi-
tivity to rolipram in transfected LLC-PK1-S#l6 cells and
controls, that is sham-transfected LLC-PK1-A# 1 cells and wild
LLC-PK1 cells, we first determined the concentration of rolip-
ram which will lower the cAMP-PDE activity in LLC-PK1-
S# 16 cells with overexpressed PDE-IV towards cAMP-PDE
activities found in sham-transfectants and wild LLC-PK1 cells
(Fig. 7, Results). We found that incubation of transfectant
LLC-PK1-S#16 cells with maximum inhibitory concentration
of rolipram which reduces cAMP-PDE activity to values which
are indistinguishable from control sham-transfectants LLC-
PK1-A#l and wild LLC-PK1 cells (Fig. 7B), the AVP-depen-
dent accumulation of cAMP in transfectants LLC-PK1-S# 16
incubated with rolipram was indistinguishable from both con-
trols: sham-transfectants and wild LLC-PK1 cells (Fig. 7A).
Since cAMP accumulation in LLC-PK1-S#l6 cells was cor-
rected only by addition of a specific cAMP-PDE inhibitor, these
observations also suggest that the transfection procedure caus-
ing an AVP-resistant clone to LLC-PK1-S#16 cells (Figs. 5 and
7) probably did impair the AVP receptor or its coupling to
adenylate cyclase. Thus, the present results are consistent with
interpretation proposing that the refractoriness of LLC-PK1-
S#16 cells to AVP could be due solely or predominantly by
overexpressed PDE-IV.
In contrast to altered cAMP dynamics, the basal cGMP levels
were not different between controls and transfectants, and the
SNP-stimulated cGMP levels is LLC-PK1-S# 16 cells were even
higher than in controls (Fig. 5, Table 2). This difference may not
be attributed to altered activities of cGMP-PDEs, either PDE-I
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or PDE-V (Fig. 5, Table 1), which did not differ between
controls and the transfectants. Perhaps factors such as altered
permeability of cells for cGMP or increased activity of guany-
late cyclase altered during the transfection procedure might
account for increased SNP-stimulated cGMP accumulation in
LLC-PK1-S#16 cells. However, the observation that SNP-
stimulated cGMP levels were not different between sham-
transfectants (LLC-PK1-A#l) and wild LLC-PK1 cells (Table
2) argues against such explanations and rather suggests that
higher cGMP levels are associated, directly or indirectly, with
increased activity of PDE-IV in LLC-PK1-S#16 cells. Thus, the
mechanism which accounts for higher cGMP accumulation in
LLC-PK1-S#16 cells remains to be explained.
The observation that treatment with rolipram, but not with
inhibitors of other PDE isozymes, elevated the AVP-dependent
cAMP levels in LLC-PK1-S#16 cells (Fig. 6) to the cAMP
values achieved by AVP alone in both controls (LLC-PK1-A#i
and wild LLC-PK1 cells; Fig. 7) affirms that the overexpressed
PDE-IV accounts for unresponsiveness to AVP. It should be
noted that the relative (%) enhancement of AVP-dependent
cAMP by roliprani was more pronounced in LLC-PK1-S#16
cells than in LLC-PK1#l cells. In control LLC-PK1-A#l cells
the PDE inhibitors had effects (Fig. 5, Table 2) analogous to
those observed in our preceding study on wild LLC-PK1 cells
[22]. However, of major interest is finding that 8-MeoM-IBMX,
a specific direct inhibitor of PDE-I [25, 35], enhanced the
stimulatory effect of AVP on cAMP (Fig. 6, Table 2). In our
preceding study of LLC-PK1 cells [22] inhibitors of calmodulin
(W-7, trifluoroperazine) and vinpocetine (direct inhibitor of
PDE-I) paradoxically decreased the AVP-dependent cAMP
accumulation, probably due to interference of these compounds
with adenylate cyclase, and the role of PDE-I, which is abun-
dant in LLC-PK1 cells, remained uncertain. The present obser-
vation that 8-MeoM-IBMX markedly (is,> + 200%) enhanced
AVP-dependent cAMP accumulation suggests that PDE-I, in
addition to PDE-IV, also participates in AVP-dependent cAMP
catabolism in LLC-PK1 cells as it does in cells of inner
medullary collecting ducts [25].
In conclusion, our results provide an argument in support of
the hypothesis that anomalously high activity of cAMP-PDE, in
this instance type PDE-IV, accounts for the resistance to
stimulatory effects of AVP upon accumulation of cAMP found
in collecting ducts of ND! mice [8—i 1]. Although measurements
of PDE activities and cAMP accumulation in microdissected
tubular segments and the analysis of the corresponding param-
eters in homogenous population of LLC-PK1 cells differ in a
number of methodologic aspects, the results yielded on these
two experimental systems are remarkably similar. In both
studies, cells with several-fold (in both cases about 4 to 6 x)
higher PDE-IV activity failed to increase cAMP, or nearly so, in
response to the maximal stimulatory doses of AVP [8, ii].
Furthermore, incubation of both AVP-resistant preparations
with rolipram in a dose which reduced cAMP-PDE activity to
levels found in controls (Fig. 7) [8] restored alone, without other
experimental maneuvers, the AVP-dependent cAMP accumu-
lation similar to that in normal control tissues. Since in trans-
fectant LLC-PK1-S#i6 cells only PDE-IV, which is predomi-
nant cAMP-PDE activity in LLC-PK1 cells [22], was selectively
increased (Figs. 1, 2, 4 and 7), and the pattern of cAMP
responses to AVP and the effect of rolipram (Fig. 7) were
analogous to findings in collecting ducts of ND! mice [8], such
comparison surmises that increased PDE-IV alone can fully
account for the AVP resistance observed in NDI mice [8—il].
In more general terms, the present study shows that stable
transfection with cDNA encoding PDE isozymes is a most
suitable and, at the present time, the only reliable experimental
strategy to study the impact of increased activities of PDE
isozymes and their subtypes upon hormone signal transduction
via cAMP and/or cGMP in intact renal cells. The present results
constitute a new argument in support of the hypothesis that
increased activity of PDE isozyme(s) and rapid cAMP catabo-
lism can be the cellular basis of resistance of collecting ducts to
antidiuretic action of AVP, and perhaps in other cAMP-medi-
ated hormonal responses [7—9, ii].
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